BeOne Medicines AG (HKG:6160)
198.00
-2.40 (-1.20%)
At close: Dec 5, 2025
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $10.05B USD in the quarter ending September 30, 2025, with 43.11% growth. This brings the company's revenue in the last twelve months to $35.40B, up 52.67% year-over-year. In the year 2024, BeOne Medicines AG had annual revenue of $27.81B with 59.51% growth.
Revenue (ttm)
$35.40B
Revenue Growth
+52.67%
P/S Ratio
7.18
Revenue / Employee
$3.22M
Employees
11,000
Market Cap
277.93B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.81B | 10.38B | 59.51% |
| Dec 31, 2023 | 17.43B | 7.67B | 78.53% |
| Dec 31, 2022 | 9.77B | 2.29B | 30.69% |
| Dec 31, 2021 | 7.47B | 5.46B | 270.56% |
| Dec 31, 2020 | 2.02B | -965.08M | -32.37% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| WuXi Biologics | 21.98B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |
| CSPC Pharmaceutical Group | 28.65B |
BeOne Medicines AG News
- 4 weeks ago - BeiGene Non-GAAP EPADS of $2.65, revenue of $1.4B beats by $40M - Seeking Alpha
- 4 weeks ago - BeiGene Q3 2025 Earnings Preview - Seeking Alpha
- 3 months ago - BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up - Benzinga
- 4 months ago - A Glimpse of BeiGene's Earnings Potential - Benzinga
- 4 months ago - BeiGene's Earnings: A Preview - Benzinga
- 4 months ago - BeiGene Q2 2025 Earnings Preview - Seeking Alpha
- 5 months ago - Glenmark Pharmaceuticals launches TEVIMBRA in India for advanced lung and esophageal cancer treatment - Business Upturn
- 6 months ago - Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval - Business Upturn